• Sandoz entered a development, manufacturing, commercialization deal with Henlius covering up to 10 biosimilars, expanding its pipeline to 39 assets.
• Terms give Sandoz global commercialization rights outside China; Henlius will lead development and manufacturing.
• Milestone-based consideration totals up to USD 322 million; near-term payments tied to initial assets could reach USD 100.5 million.
• Initial assets include proposed biosimilars of cetuximab, evolocumab, belimumab; option added for recombinant human hyaluronidase.
• Pipeline could rise to as many as 46 assets, positioning the company for biosimilar loss-of-exclusivity opportunities over the next decade.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sandoz Group AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2379502_en) on August 17, 2026, and is solely responsible for the information contained therein.